RhumbLine Advisers’s Juno Therapeutics, Inc. JUNO Stock Holding History

RhumbLine Advisers’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-61,919	Closed	-$2.83M	–	2836
2017 Q4	$2.83M	Buy	61,919 +1,493	+2%	+$74.5K	0.01%	1422
2017 Q3	$2.71M	Buy	60,426 +784	+1%	+$26.7K	0.01%	1409
2017 Q2	$1.78M	Sell	59,642 -9,844	-14%	-$243K	﹤0.01%	1656
2017 Q1	$1.54M	Buy	69,486 +3,853	+6%	+$82.6K	﹤0.01%	1697
2016 Q4	$1.24M	Buy	65,633 +5,820	+10%	+$142K	﹤0.01%	1737
2016 Q3	$1.79M	Buy	59,813 +4,462	+8%	+$139K	﹤0.01%	1481
2016 Q2	$2.13M	Buy	55,351 +44,647	+417%	+$1.85M	0.01%	1296
2016 Q1	$408K	Sell	10,704 -250	-2%	-$8.71K	﹤0.01%	2356
2015 Q4	$482K	Buy	10,954 +570	+5%	+$28.3K	﹤0.01%	2258
2015 Q3	$423K	Buy	10,384 +637	+7%	+$27.9K	﹤0.01%	2338
2015 Q2	$520K	Buy	+9,747	New	+$517K	﹤0.01%	2303

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

RhumbLine Advisers's JUNO Position: Q1 2018 in Review

RhumbLine Advisers sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 61,919 shares — an estimated $2.83M sold.

RhumbLine Advisers first reported a position in JUNO in Q2 2015 and held it in 11 quarters. The position peaked at $2.83M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

RhumbLine Advisers reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
RhumbLine Advisers sold 61,919 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $2.83M.
RhumbLine Advisers first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 11 quarters.
RhumbLine Advisers's Juno Therapeutics, Inc. position peaked at $2.83M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on RhumbLine Advisers's 13F filing for Q1 2018, filed 2 May 2018.